LOXL2 participates in the repression of E-cadherin CDH1, a hallmark of the epithelial to mesenchymal transition (EMT) that is believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression 19. Here, LOXL2 is linked to neoplasm.